1) The CANTOS trial tested the effects of the IL-1β inhibitor canakinumab on cardiovascular outcomes in patients with prior myocardial infarction and residual inflammatory risk. 2) A pre-specified secondary analysis found that canakinumab reduced HbA1c levels in patients with pre-diabetes over 9-12 months but effects were attenuated over time. 3) Canakinumab did not significantly reduce the risk of progression from pre-diabetes to diabetes, though it reduced inflammatory biomarkers hsCRP and IL-6 known to be associated with new onset diabetes.